A growing shortage of Cisplatin and Carboplatin is creating significant challenges for oncology services across India, with hospitals reporting dwindling inventories and patients struggling to secure the essential chemotherapy agents needed for ongoing treatment. The supply disruption has begun affecting treatment planning at both public and private institutions, prompting concerns among oncologists about the potential impact on patients receiving curative-intent therapy. Cisplatin and Carboplatin remain integral components of treatment protocols for a broad range of malignancies, including lung, ovarian, cervical, breast, oral cavity, esophageal, testicular, and gallbladder cancers.
At several centers, clinicians report that available stocks are running critically low. Dr. Shyam Aggarwal, Chairman of Medical Oncology at Sir Ganga Ram Hospital, described the situation as increasingly…
